Vis enkel innførsel

dc.contributor.authorBerg, Kari Hansen
dc.contributor.authorRohde, Gudrun Elin
dc.contributor.authorPripp, Are Hugo
dc.contributor.authorPrøven, Anne
dc.contributor.authorBenestad, Espen Esther Pirelli
dc.contributor.authorØstensen, Monika Elisabeth
dc.contributor.authorHaugeberg, Glenn
dc.date.accessioned2021-03-18T11:57:18Z
dc.date.available2021-03-18T11:57:18Z
dc.date.created2020-11-16T09:35:27Z
dc.date.issued2020
dc.identifier.issn1462-0324
dc.identifier.urihttps://hdl.handle.net/11250/2734191
dc.description.abstractObjective To explore patient perception of sexual quality of life (SQOL), an important category of QOL, in male and female patients with axial SpA (axSpA) after a 5 year follow-up. Methods A broad spectrum of demographic, disease-related, treatment and SQOL data was collected at baseline and at the 5 year follow-up. SQOL was assessed by the SQOL-Female (SQOL-F) questionnaire. For statistical analysis, McNemar’s tests, paired t-tests and multiple regression analyses were applied. Results A total of 245 axSpA patients (168 men and 77 women) from outpatient clinics were examined (mean age 46 years, mean disease duration 11.9 years at baseline). Compared with baseline, the patients had lower CRP, lower Maastricht Ankylosing Spondylitis Enthesitis Scores, lower BASFI scores, less use of smoking and significantly more patients were treated with biologic DMARDs at the 5 year follow-up. Patient perception of SQOL was basically unchanged at the 5 year follow-up despite a significantly increased proportion of comorbidities, including cardiovascular, endocrine and gastrointestinal disease. A decrease in SQOL after 5 years was observed only in patients exercising <1 h/week at baseline (P = 0.048) and in patients >65 years old. Conclusion In our axSpA patients, no statistically significant changes in SQOL were observed over 5 years, despite a significant increase in comorbidities. Overall disease symptoms decreased, indicating better disease control. Increased use of biologic drugs at the 5 year follow-up may have contributed to this favourable outcome.en_US
dc.language.isoengen_US
dc.publisherOxford University Pressen_US
dc.titleIncreased Proportion of Comorbidities but no Deterioration of sexual QOL during a 5-year follow-up in Patients with ax-SpA in the biologic Treatment Eraen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionacceptedVersionen_US
dc.source.journalRheumatologyen_US
dc.identifier.doihttps://doi.org/10.1093/rheumatology/keaa887
dc.identifier.cristin1848190
dc.description.localcodeLocked until 7.1.2022 due to copyright restrictions. This is a pre-copyedited, author-produced version of an article accepted for publication following peer review. The version of record is available online at: https://doi.org/10.1093/rheumatology/keaa887en_US
cristin.ispublishedfalse
cristin.fulltextpostprint
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel